Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,616 across all filing types
Latest filing 2021-05-28 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
独立董事关于第八届董事局第二十次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding a specific board meeting matter about the transfer of subsidiary accounts receivable. It references governance rules and provides an opinion on a board resolution. The document is short (418 characters) and does not contain financial statements or detailed financial data. It is not a full report but rather a governance-related opinion tied to board decisions. This fits best under Board/Management Information (MANG), which covers announcements related to board or senior management matters.
2021-05-28 Chinese
第八届董事局第二十次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of a board meeting resolution by Shenzhen Haiwang Bioengineering Co., Ltd. It details the convening of the 20th meeting of the 8th board, the agenda discussed, and the voting results. There is no financial data, no detailed report, no audit information, or other types of filings. It is clearly a Board/Management Information announcement about board decisions and resolutions. The document length is short and it is not an announcement of a report publication but a direct disclosure of board meeting outcomes.
2021-05-28 Chinese
北京德恒（深圳）律师事务所关于深圳市海王生物工程股份有限公司2020年年度股东大会的法律意见
AGM Information Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the legality and procedural compliance of the 2020 Annual General Meeting (AGM) of Shenzhen Haier Bioengineering Co., Ltd. It details the convening, attendance, voting procedures, and results of the AGM. The document does not contain financial statements or management discussion but focuses on the legal validation of the AGM process and resolutions. It is not the AGM materials or presentations themselves but a legal opinion related to the AGM. Therefore, it fits best under the category of AGM Information (AGM-R), which includes presentations and materials shared during the AGM, including legal opinions related to the meeting.
2021-05-20 Chinese
2020年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2020 Annual General Meeting (AGM) of Shenzhen Haier Bioengineering Co., Ltd. It includes voting results on various proposals such as the 2020 board report, supervisory board report, financial statements, profit distribution plan, annual report approval, auditor appointment, related party transactions, and guarantees. The document also confirms the legality and validity of the meeting and voting process, with legal opinions attached. The content is focused on the AGM meeting details and voting outcomes rather than the full annual report or financial statements themselves. The document length is about 4662 characters, which is relatively short and consistent with an announcement of voting results rather than the full report. Therefore, the document fits best into the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2021-05-20 Chinese
关于为控股子公司提供担保实施情况的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the implementation of guarantees provided to its controlling subsidiaries. It details specific guarantee contracts signed with various banks for credit facilities extended to subsidiaries, including amounts, guarantee scope, and periods. The document includes cumulative guarantee amounts and their proportion to the company's audited net assets. There is no financial statement or comprehensive financial analysis present, nor is it a report like an annual or interim report. It is a regulatory announcement about guarantees provided, which relates to capital or financing activities. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is over 5,000 characters and contains substantive details about financing guarantees, not merely a brief notice or certification, so it is not RNS or RPA.
2021-05-10 Chinese
年度关联方资金占用专项审计报告
Audit Report / Information Classification · 95% confidence The document is a detailed special explanation regarding non-operating fund occupation and other related party fund transactions of Shenzhen Haier Bioengineering Co., Ltd. for the year 2020. It includes audited financial data and tables summarizing related party transactions and fund balances. The document references an audit report with an unqualified opinion and complies with regulatory requirements from the China Securities Regulatory Commission and the State-owned Assets Supervision and Administration Commission. The content is a standalone audit-related report focusing on specific financial and related party transaction disclosures, not a full annual report or interim report. It is not a mere announcement or certification but contains substantive audited financial data and explanations. Therefore, it fits the category of an Audit Report / Information (AR).
2021-04-26 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.